OMEROS CORP

Company Overview

Omeros Corporation (OMER) is a clinical‑stage biopharmaceutical company focused on complement‑targeted and PDE7 programs, with lead monoclonal antibody candidates narsoplimab (MASP‑2, BLA resubmitted and accepted) and zaltenibart (MASP‑3, Phase 3 in PNH). The company is vertically coordinated for R&D (136 R&D employees) and outsources commercial‑scale manufacturing to contract partners such as Lonza and Vetter, while retaining worldwide commercialization rights and an extensive global patent estate. Financially, Omeros has relied on OMIDRIA monetizations, milestone cash inflows and a secured Term Loan; it runs material liquidity and covenant risk (a $25M minimum cash covenant) and has disclosed substantial doubt about near‑term going concern without further financing. Regulatory timing (FDA PDUFA/EMA review), clinical readouts, third‑party manufacturing scale‑up, and reimbursement dynamics are the primary near‑term value drivers and risks.

Executive Compensation Practices

Given the company’s late‑stage clinical profile, small R&D headcount and constrained cash runway, executive pay at Omeros is likely skewed toward equity‑linked and milestone‑driven compensation (stock options, RSUs, and approval/licensing bonus triggers) to conserve cash while aligning management with binary regulatory and commercial outcomes. Short‑term cash bonuses and salary budgets are likely modest relative to peers and may be constrained by debt covenants and the need to preserve liquidity; retention awards (time‑vested equity) are common to keep key scientific and commercial hires. If narsoplimab is approved and commercial launch proceeds, compensation mix would likely shift to include commercialization‑linked incentives (sales targets, launch milestones) and broader SG&A‑related variable pay tied to payer access and revenue metrics. The company’s use of milestone monetizations and periodic equity/debt financings also increases the probability of one‑time transactional compensation (change‑of‑control or milestone severance/bonuses) for senior executives.

Insider Trading Considerations

Insider trading activity at Omeros is likely to cluster around regulatory and financing catalysts — e.g., BLA/MAA decisions (PDUFA Dec 26, 2025 per recent filings), Phase‑3 milestones for zaltenibart, OMIDRIA monetization events, and registered offerings or exchanges — with typical blackout windows before material announcements. Because management compensation and a meaningful portion of employee wealth are probably equity‑based, look for exercises, option sales and planned Form 4 disclosures tied to financing events or diversification needs; conversely, open‑market purchases by insiders ahead of approvals would be a stronger signal of confidence. Expect 10b5‑1 plans, lock‑up/transfer restrictions tied to financing transactions, and Section 16 reporting; also monitor whether lenders or the secured Credit Agreement impose additional transfer or trading restrictions on key holders that could suppress visible insider sales.